Month: August 2025

Highlights• SQM reported total revenues for the six months ended June 30, 2025 of US$2,079.3 million compared to total revenues of US$2,378.1 million for the same period last year.• Net income for the six months ended June 30, 2025 of US$226.0 million or US$0.79 per share, compared to net loss of US$(655.9) million or US$(2.30) per share for the same period last year.• Continue to observe record- high iodine sales price.• Strong price environment in SPN and Potassium businesses.• Increasing sales volumes for the coming months from the International Lithium Division and completion of the Kwinana refinery.SQM will hold a conference call to discuss these results on Wednesday, August 20, 2025 at 12:00pm EDT (12:00pm Chile time).Participant Call link: https://register-conf.media-server.com/register/BI096c4f4e6f094d1db8eba9c6ed4a9bbdWebcast:...

High activity and solid profitability AKVA group delivered record high quarterly revenue in Q2 2025 of MNOK 1 167 (1 014), an increase of 15% compared to Q2 2024. EBITDA increased from MNOK 110 in Q2 2024 to MNOK 145 in Q2 2025. Total order intake of BNOK 1,1 in Q2 2025, up from MNOK 888 in Q2 2024. Order backlog was BNOK 2,7 at the end of June 2025. A new land-based contract with Laxey was signed in May 2025 with contract value of approx. MEUR 20. Another land-based contract was awarded mid-July from Laxey with estimated contract value of MEUR 8.5. The activity level in the second quarter of 2025 was high with revenue of MNOK 1 167 and order intake of MNOK 1 052. The order intake in the quarter was supported by the award of land-based contract from Laxey with estimated contract value of MEUR 20. Profitability improved significantly...

Highlights Shauna McIntyre appointed new CEO of EnsurgeMicropower ASA New Board of Directors Successfully completed two comprehensive batteryevaluations for a customer as part of its initialdelivery order Progressed manufacturing from individual sheet-based production towards its intended productionline of roll-to-roll (R2R) production in the front-endcell manufacturing Progress on technology cooperation with a Fortune500 company Signed an additional evaluation agreement with amedical device company Progressing Joint Development Agreements (JDAs)with Evaluation Partners to fund the company’stechnological development Future quarterly reports will be presented by our CEO Shauna McIntyre either in person or by a webcast  About Ensurge Micropower Ensurge is energizing innovation with the first ultrathin, flexible, reliable, and fundamentally...

COMPANY ANNOUNCEMENT NO. 23-2025 FLSmidth & Co. A/S 20 August 2025 Copenhagen, DenmarkToday, the Board of Directors of FLSmidth have approved the H1 2025 Interim Financial Report. Highlights in Q2 2025:Continued and disciplined execution of our strategic priorities despite macroeconomic and geopolitical uncertainties Further reduction in SG&A driving strong progression in underlying profitability, with an Adjusted EBITA margin of 15.2% Solid organic order intake growth in PC&V and Products, whereas organic Service order intake is slightly down versus Q2 2024 Solid cash flow generation and launch of the company’s first share buy-back programme since 2012 Signed agreements to sell the Cement business and corporate headquarters in Copenhagen The financial guidance for the full year 2025 was updated on 14 August 2025 (ref....

Q2 2025 INTERIM REPORT ANNOUNCEMENT NO. 25/2025Q2 2025Revenue up 3% to DKK 7.8bn Organic growth was -2% EBIT reduced 69% to DKK 163m Adjusted free cash flow of DKK 538m CO2 ferry emission intensity from own fleet lowered 4.1%Outlook 2025EBIT of DKK 0.8-1.0bn (previously around DKK 1.0bn) Revenue growth of around 5% Adjusted free cash flow of around DKK 1.0bn (unchanged)“Most of the network performed in line with our expectations for the quarter. The Mediterranean activities remain our key earnings challenge,” says Torben Carlsen, CEO.  Q2 Q2 Change, LTM LTM Change, Full-yearDKK m 2025 2024 % 2024-25 2023-24 % 2024               Revenue 7,810 7,580 3 30,510 28,613 7 29,753EBITDA 893 1,232 -28 3,892 4,737 – 18 4,440EBIT 163 519 -69 833 1,963 – 58 1,506Adjusted free cash flow 538 724 -26 1,344 2,311 –...

Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its second quarter 2025 results today. Webcast scheduled for 20 August 2025, at 09:00 (CET). Link to webcast here. Second Quarter 2025 Business Update HighlightsOn track toward IND/CTA submission in 2H 2025 and first-in-human trial initiation in 1H 2026. Broadened regulatory engagement: following positive FDA pre-IND feedback (Q2 2024), submitted a scientific advice briefing package to the UK MHRA in July 2025 for ZI-MA4-1. Initiated GMP manufacturing of clinical material in July 2025, a major step in clinical readiness; scalable platform developed with Catalent can deliver hundreds of doses from a single batch. Strong support from leading...